Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

PR Newswire September 26, 2023

LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

PR Newswire September 19, 2023

LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

PR Newswire September 15, 2023

LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

PR Newswire September 12, 2023

LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP

PR Newswire August 16, 2023

Liminal BioSciences Reports Second Quarter Financial Results 2023

PR Newswire August 8, 2023

Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP

PR Newswire July 12, 2023

Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders

PR Newswire June 5, 2023

Liminal BioSciences Provides R&D Update

PR Newswire June 2, 2023

Liminal BioSciences Reports First Quarter Financial Results 2023

PR Newswire May 9, 2023

The Special Committee of the Board of Directors of Liminal Biosciences Retains an Independent Financial Advisor in Response to Unsolicited Non-Binding Transaction Proposal

PR Newswire May 8, 2023

Liminal Biosciences Confirms Receipt of Unsolicited Non-Binding Transaction Proposal

PR Newswire April 5, 2023

THOMVEST SUBMITS PROPOSAL TO ACQUIRE LIMINAL BIOSCIENCES ON AN ALL CASH BASIS

Canada NewsWire April 5, 2023

Liminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results

PR Newswire March 15, 2023

Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023

PR Newswire March 13, 2023

Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement

PR Newswire February 15, 2023

Liminal BioSciences Announces Reverse Stock Split

PR Newswire January 26, 2023

Liminal BioSciences to Present at BIO CEO & Investor Conference

Canada NewsWire January 19, 2023

Liminal BioSciences Announces Priorities For 2023

PR Newswire January 6, 2023

Liminal BioSciences Announces Holding of Special Meeting of Shareholders

PR Newswire November 25, 2022